Drugs for Age-Related Macular Degeneration
Drugs for Age-Related Macular Degeneration
January 6, 2025 (Issue: 1719)
Age-related macular degeneration (AMD) has two
major forms: dry or non-neovascular (~90% of
patients) and wet or neovascular (~10% of patients).
REFERENCES
- M Fleckenstein et al. Age-related macular degeneration: a review. JAMA 2024; 331:147. doi:10.1001/jama.2023.26074
- Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309:2005. doi:10.1001/jama.2013.4997
- D Desai and PU Dugel. Complement cascade inhibition in geographic atrophy: a review. Eye (Lond) 2022; 36:294. doi:10.1038/s41433-021-01765-x
- GJ Jaffe et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology 2021; 128:576. doi:10.1016/j.ophtha.2020.08.027
- AM Khanani et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 2023; 402:1449. doi:10.1016/s0140-6736(23)01583-0
- SS Patel et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond) 2023; 37:3551. doi:10.1038/s41433-023-02497-w
- JS Heier et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 2023; 402:1434. doi:10.1016/s0140-6736(23)01520-9
- Valeda light delivery system for age-related macular degeneration. Med Lett Drugs Ther 2024 December 11 (epub).
- D Boyer et al. LIGHTSITE III: 13-month efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative (dry) age-related macular degeneration using the Lumithera Valeda Light Delivery System. Retina 2024; 44:487. doi:10.1097/iae.0000000000003980
- VEGF inhibitors for AMD and diabetic macular edema. Med Lett Drugs Ther 2015; 57:41.
- Ranibizumab (Lucentis) for macular degeneration. Med Lett Drugs Ther 2006; 48:85.
- PJ Rosenfeld et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419. doi:10.1056/nejmoa054481
- A ranibizumab ocular implant (Susvimo) for age-related macular degeneration. Med Lett Drugs Ther 2022; 64:71.
- NM Holekamp et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2022; 129:295. doi:10.1016/j.ophtha.2021.09.016
- BA Frost and MA Kainer. Safe preparation and administration of intravitreal bevacizumab injections. N Engl J Med 2011; 365:2238. doi:10.1056/nejmc1105759
- CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897. doi:10.1056/nejmoa1102673
- U Chakravarthy et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382:1258. doi:10.1016/s0140-6736(13)61501-9
- CATT Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119:1388. doi:10.1016/j.ophtha.2012.03.053
- Aflibercept (Eylea) for age-related macular degeneration. Med Lett Drugs Ther 2012; 54:9.
- P Lanzetta et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 2024; 403:1141. doi:10.1016/s0140-6736(24)00063-1
- PU Dugel et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 2020; 127:72. doi:10.1016/j.ophtha.2019.04.017
- Brolucizumab (Beovu) for age-related macular degeneration. Med Lett Drugs Ther 2020; 62:23.
- Addendum: Brolucizumab (Beovu) for age-related macular degeneration. Med Lett Drugs Ther 2020; 62:40.
- JS Heier et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 2022; 399:729. doi:10.1016/s0140-6736(22)00010-1
- Faricimab (Vabysmo) for age-related macular degeneration and diabetic macular edema. Med Lett Drugs Ther 2022; 64:45.
- GB Melo et al. The risks behind the widespread use of siliconized syringes in the healthcare practice. Int J Retina Vitreous 2021; 7:66. doi:10.1186/s40942-021-00338-0
- Photodynamic therapy with verteporfin (Visudyne) for macular degeneration. Med Lett Drugs Ther 2000; 42:81.
- Y Gao et al. Anti-VEGF monotherapy versus photodynamic therapy and anti-VEGF combination treatment for neovascular age-related macular degeneration: a meta-analysis. Invest Ophthalmol Vis Sci 2018; 59:4307. doi:10.1167/iovs.17-23747
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Age-Related Macular Degeneration
Article code: 1719a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
